Lack of utility of plasma TNF-α level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer

Cytokine

Volumn 51, Issue 3, 2010, Pages 245-248

  Kumar, Sachin ^a   Guleria, Randeep ^a   Singh, Vikas ^a   Mohan, Anant ^a   Bharti, Alok C ^b   Das, Bhudev C ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Biomarker; Chemotherapy; Response; Sensitivity; Specificity

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955266207     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.05.007     Document Type: Article

References (11)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Gridelli C., Rossi A., Maione P. Treatment of non-small cell lung cancer: state of the art and development of new biological agents. Oncogene 2003, 22:6629-6638.
3. van Horssen R., Ten Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408.
4. O'Brien M.E., Saini A., Smith I.E., Webb A., Gregory K., Mendes R., et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000, 83:853-857.
5. Tas F., Duranyi{dotless}ldi{dotless}z D., Argon A., Oĝuz H., Camlica H., Yasasever V., et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 2005, 22:353-358.
6. Derin D., Soydinc H.O., Guney N., Tas F., Camlica H., Duranyildiz D., et al. Serum levels of apoptosis biomarkers, surviving and TNF-alpha in non-small cell lung cancer. Lung Cancer 2008, 59:240-245.
7. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
8. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994, 73:2013-2026.
9. Martín F., Santolaria F., Batista N., Milena A., González-Reimers E., Brito M.J., et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999, 11:80-86.
10. Kaminska J., Kowalska M., Kotowicz B., Fuksiewicz M., Glogowski M., Wojcik E., et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis M-CSF-an independent prognostic factor. Oncology 2006, 70:115-125.
11. Enewold L., Mechanic L.E., Bowman E.D., Zheng Y.L., Yu Z., Trivers G., et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009, 18:215-222.